AU2002327426C1 - Adenosine A3 receptor agonists - Google Patents
Adenosine A3 receptor agonists Download PDFInfo
- Publication number
- AU2002327426C1 AU2002327426C1 AU2002327426A AU2002327426A AU2002327426C1 AU 2002327426 C1 AU2002327426 C1 AU 2002327426C1 AU 2002327426 A AU2002327426 A AU 2002327426A AU 2002327426 A AU2002327426 A AU 2002327426A AU 2002327426 C1 AU2002327426 C1 AU 2002327426C1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- optionally substituted
- formula
- hydroxymethyl
- purin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31106901P | 2001-08-08 | 2001-08-08 | |
| US60/311,069 | 2001-08-08 | ||
| PCT/US2002/024696 WO2003014137A1 (en) | 2001-08-08 | 2002-08-06 | Adenosine a3 receptor agonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| AU2002327426A2 AU2002327426A2 (en) | 2003-02-24 |
| AU2002327426A1 AU2002327426A1 (en) | 2003-06-19 |
| AU2002327426B2 AU2002327426B2 (en) | 2007-06-14 |
| AU2002327426C1 true AU2002327426C1 (en) | 2008-03-06 |
Family
ID=23205248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002327426A Ceased AU2002327426C1 (en) | 2001-08-08 | 2002-08-06 | Adenosine A3 receptor agonists |
Country Status (20)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| EP2048142A3 (en) * | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| AU2002362443B2 (en) | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
| US6914053B2 (en) * | 2002-09-09 | 2005-07-05 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
| WO2004086034A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3) |
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| US7442687B2 (en) | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| NZ585697A (en) | 2004-08-02 | 2011-12-22 | Univ Virginia Patent Found | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| CN101083998A (zh) * | 2004-11-22 | 2007-12-05 | 王者制药研究发展有限公司 | 用腺苷a3受体激动剂强化治疗hif-1介导的病症 |
| EP1845973B1 (en) | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| GB0505219D0 (en) * | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
| US7381714B2 (en) * | 2005-05-19 | 2008-06-03 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| US7514417B2 (en) | 2005-05-19 | 2009-04-07 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7488720B2 (en) | 2005-10-13 | 2009-02-10 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| US7589076B2 (en) * | 2006-05-18 | 2009-09-15 | Pgx Health, Llc | Substituted aryl piperidinylalkynyladenosines as A2AR agonists |
| US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| DE102007012645A1 (de) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| JP5703432B2 (ja) * | 2007-03-28 | 2015-04-22 | ノイロサーチ アクティーゼルスカブ | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| EP2142546B1 (en) | 2007-03-28 | 2017-06-07 | Saniona A/S | Purinyl derivatives and their use as potassium channel modulators |
| US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| JP2011500716A (ja) * | 2007-10-16 | 2011-01-06 | ギリアード・パロ・アルト・インコーポレイテッド | A3アデノシン受容体アンタゴニスト |
| US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| RU2451010C1 (ru) * | 2011-01-11 | 2012-05-20 | Закрытое Акционерное Общество "Ива Фарм" | Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия |
| EP2885290B1 (en) | 2012-06-26 | 2017-10-18 | Saniona A/S | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| CN120647702A (zh) * | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| US20220332750A1 (en) * | 2019-06-21 | 2022-10-20 | Academy Of Military Medical Sciences | Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof |
| JP2024502068A (ja) * | 2020-12-29 | 2024-01-17 | チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド | A3アデノシン受容体アゴニスト及びその調製方法と用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6180615B1 (en) * | 1999-06-22 | 2001-01-30 | Cv Therapeutics, Inc. | Propargyl phenyl ether A2A receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
-
2002
- 2002-08-05 US US10/212,896 patent/US20030078232A1/en not_active Abandoned
- 2002-08-06 AU AU2002327426A patent/AU2002327426C1/en not_active Ceased
- 2002-08-06 ES ES02763415T patent/ES2247371T3/es not_active Expired - Lifetime
- 2002-08-06 KR KR1020047001949A patent/KR100923888B1/ko not_active Expired - Fee Related
- 2002-08-06 PL PL02368205A patent/PL368205A1/xx not_active Application Discontinuation
- 2002-08-06 DK DK02763415T patent/DK1414837T3/da active
- 2002-08-06 WO PCT/US2002/024696 patent/WO2003014137A1/en not_active Ceased
- 2002-08-06 HU HU0401437A patent/HUP0401437A3/hu unknown
- 2002-08-06 EP EP02763415A patent/EP1414837B1/en not_active Expired - Lifetime
- 2002-08-06 CA CA002456744A patent/CA2456744A1/en not_active Abandoned
- 2002-08-06 RU RU2004106635/04A patent/RU2298557C2/ru not_active IP Right Cessation
- 2002-08-06 DE DE60206775T patent/DE60206775T2/de not_active Expired - Lifetime
- 2002-08-06 CN CNB02815486XA patent/CN1244589C/zh not_active Expired - Fee Related
- 2002-08-06 MX MXPA04001185A patent/MXPA04001185A/es active IP Right Grant
- 2002-08-06 IL IL16023102A patent/IL160231A0/xx unknown
- 2002-08-06 AT AT02763415T patent/ATE307136T1/de not_active IP Right Cessation
- 2002-08-06 NZ NZ530976A patent/NZ530976A/en not_active IP Right Cessation
- 2002-08-06 JP JP2003519086A patent/JP4357960B2/ja not_active Expired - Fee Related
-
2004
- 2004-02-05 IL IL160231A patent/IL160231A/en not_active IP Right Cessation
- 2004-02-06 ZA ZA200401000A patent/ZA200401000B/en unknown
- 2004-03-05 NO NO20040969A patent/NO327997B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1414837A1 (en) | 2004-05-06 |
| KR100923888B1 (ko) | 2009-10-28 |
| HUP0401437A2 (hu) | 2004-11-29 |
| JP4357960B2 (ja) | 2009-11-04 |
| AU2002327426A2 (en) | 2003-02-24 |
| PL368205A1 (en) | 2005-03-21 |
| DE60206775D1 (de) | 2006-03-02 |
| RU2004106635A (ru) | 2005-07-27 |
| EP1414837B1 (en) | 2005-10-19 |
| RU2298557C2 (ru) | 2007-05-10 |
| ZA200401000B (en) | 2004-10-18 |
| NO20040969L (no) | 2004-04-19 |
| US20030078232A1 (en) | 2003-04-24 |
| IL160231A0 (en) | 2004-07-25 |
| IL160231A (en) | 2010-11-30 |
| CN1244589C (zh) | 2006-03-08 |
| NO327997B1 (no) | 2009-11-09 |
| DE60206775T2 (de) | 2006-07-20 |
| CN1538972A (zh) | 2004-10-20 |
| KR20040023733A (ko) | 2004-03-18 |
| HUP0401437A3 (en) | 2007-05-29 |
| WO2003014137A1 (en) | 2003-02-20 |
| NZ530976A (en) | 2005-07-29 |
| ES2247371T3 (es) | 2006-03-01 |
| DK1414837T3 (da) | 2005-11-07 |
| CA2456744A1 (en) | 2003-02-20 |
| AU2002327426B2 (en) | 2007-06-14 |
| ATE307136T1 (de) | 2005-11-15 |
| MXPA04001185A (es) | 2005-06-17 |
| JP2005501842A (ja) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002327426B2 (en) | Adenosine A3 receptor agonists | |
| AU2002327426A1 (en) | Adenosine A3 receptor agonists | |
| US7262176B2 (en) | Adenosine A3 receptor agonists | |
| JP5042996B2 (ja) | A1アデノシンレセプターアゴニスト | |
| US7163928B2 (en) | Partial and full agonists of A1 adenosine receptors | |
| US6914053B2 (en) | Adenosine A3 receptor agonists | |
| US20090137520A1 (en) | A1 adenosine receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 FEB 2004 |
|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 SEP 2007. |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 SEP 2007 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE NAME FROM CV THERAPEUTICS, INC. TO GILEAD PALO ALTO, INC. |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |